GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (OTCPK:NVLNF) » Definitions » Insider Ownership

Novelion Therapeutics (Novelion Therapeutics) Insider Ownership : 8.13 % (As of Apr. 28, 2024)


View and export this data going back to 1988. Start your Free Trial

What is Novelion Therapeutics Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Novelion Therapeutics's insider ownership is 8.13%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Novelion Therapeutics's Institutional Ownership is 61.68%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Novelion Therapeutics's Float Percentage Of Total Shares Outstanding is 81.52%.


Novelion Therapeutics Insider Ownership Historical Data

The historical data trend for Novelion Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novelion Therapeutics Insider Ownership Chart

Novelion Therapeutics Historical Data

The historical data trend for Novelion Therapeutics can be seen below:

2019-03-31 2019-04-30 2019-05-31 2019-06-30 2019-07-31 2019-08-31 2019-09-30 2019-10-31 2019-11-30 2019-12-31
Insider Ownership 8.40 8.40 8.40 8.40 8.40 8.40 8.13 8.13 8.13 8.13

Novelion Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Novelion Therapeutics (Novelion Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
c/o Norton Rose Fulbright, 1800 West Georgia Street, Suite 510, Vancouver, BC, CAN, V6B 0M3
Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.
Executives
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Stonepine Capital, L.p. 10 percent owner 919 NW BOND STREET, SUITE 204, BEND OR 97703
Michael Dennis Price officer: Chief Financial Officer
Benjamin Harshbarger officer: See Remarks ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
John J Orloff director C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Stephen L Sabba director DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
Mark Corrigan director
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Murray Stewart officer: Executive Vice President, R&D C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3
Jason Aryeh director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Mary T Szela director, officer: Chief Executive Officer 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121